Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

• Status: Recruiting
• Trial end date: 2027-03-01

Summary

This is a national clinical trial, multicentric (28 centers), non-randomized phase 2 study.

Population: Patients with previously untreated Richter's syndrome (RS), defined as the occurrence of an aggressive lymphoma (of diffuse large B-cell lymphoma histology) in a patient with chronic lymphocytic leukemia (CLL).

Study treatment:

The duration of each cycle is 21 days.

Cycle 1:

Participants will receive standard of care doses of R-CHOP in cycle 1 as follows:

• Rituximab 375 mg/m² IV Day 1

• Cyclophosphamide 750 mg/m² IV Day 1

• Doxorubicin 50 mg/m² IV Day 1

• Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1

• Prednisone 60 mg/m2 per day PO Day 1-5

Cycle 2:

In order to minimize cytokine release syndrome (CRS), participants will then receive G-CHOP as cycle 2 (with obinutuzumab) and glofitamab:

• Obinutuzumab 1000 mg single dose IV Day 1

• Cyclophosphamide 750 mg/m² IV Day 1

• Doxorubicin 50 mg/m² IV Day 1

• Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1

• Prednisone 60 mg/m2 per day PO Day 1-5

• Glofitamab : administered intravenously (IV) as a step-up dose on Days 8 (2.5 mg) and 15 (10 mg)

Cycle 3-6:

Participants will receive standard of care doses of R-CHOP and Glofitamab as follows:

• Rituximab 375 mg/m² IV Day 1

• Cyclophosphamide 750 mg/m² IV Day 1

• Doxorubicin 50 mg/m² IV Day 1

• Vincristine 1.4 mg/m² [capped at 2.0 mg] IV Day 1

• Prednisone 60 mg/m2 per day PO Day 1-5

• Glofitamab : 30 mg IV Day 8

Cycle 7 and 8 (only for patient in Complete Response or Partial response after Cycle 6):

Cycle 7 and 8 consist of 2 infusions of glofitamab only at D8C7 and D8C8:

● Glofitamab : 30 mg IV Day 8

Primary endpoint Percentage of participants with a complete response as assessed by the investigator using the Cheson IWG 2014 Lugano Classification (i.e. Deauville scale 1-3) after 6 cycles of R/G-CHOP + glofitamab or at permanent treatment discontinuation.

End of treatment is defined as after 6 cycles of R/G-CHOP + glofitamab. Permanent treatment discontinuation is defined as the discontinuation of all treatments (R/G-CHOP, glofitamab).

• Phase: Phase 2

Details

• Lead Sponsor: French Innovative Leukemia Organisation
• Collaborator: Hoffmann-La Roche
• Treatments: Obinutuzumab